Augmentation treatment in major depressive disorder: focus on aripiprazole. by Nelson, J Craig et al.
UCSF
UC San Francisco Previously Published Works
Title
Augmentation treatment in major depressive disorder: focus on aripiprazole.
Permalink
https://escholarship.org/uc/item/2wt5p69r
Journal
Neuropsychiatric Disease and Treatment, 4(5)
ISSN
1176-6328
Authors
Nelson, J Craig
Pikalov, Andrei
Berman, Robert M
Publication Date
2008-10-01
DOI
10.2147/ndt.s3369
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
© 2008 Dove Medical Press Limited.  All rights reserved
Neuropsychiatric Disease and Treatment 2008:4(5) 937–948 937
E X P E RT  O P I N I O N
Augmentation treatment in major depressive 
disorder: focus on aripiprazole
J Craig Nelson1
Andrei Pikalov2
Robert M Berman3
1University of California San 
Francisco, San Francisco, California, 
USA; 2Otsuka Pharmaceutical Inc., 
Rockville, MD, USA; 3Bristol-Myers 
Squibb, Wallingford, CT, USA
Correspondence: J Craig Nelson
University of California San Francisco, 
401 Parnussus Avenue, Box 0984-F, 
San Francisco, CA 94143, USA
Tel +1 415 476 7000
Email craign@lppi.ucsf.edu
Abstract: Major depressive disorder (MDD) is a disabling psychiatric condition for which 
effective treatment remains an outstanding need. Antidepressants are currently the mainstay of 
treatment for depression; however, almost two-thirds of patients will fail to achieve remission 
with initial treatment. As a result, a range of augmentation and combination strategies have 
been used in order to improve outcomes for patients. Despite the popularity of these approaches, 
limited data from double-blind, randomized, placebo-controlled studies are available to allow 
clinicians to determine which are the most effective augmentation options or which patients are 
most likely to respond to which options. Recently, evidence has shown that adjunctive therapy 
with atypical antipsychotics has the potential for benefi cial antidepressant effects in the absence 
of psychotic symptoms. In particular, aripiprazole has shown effi cacy as an augmentation option 
with standard antidepressant therapy in two, large, randomized, double-blind studies. Based 
on these effi cacy and safety data, aripiprazole was recently approved by the FDA as adjunctive 
therapy for MDD. The availability of this new treatment option should allow more patients with 
MDD to achieve remission and, ultimately, long-term, successful outcomes.
Keywords: major depression, antipsychotic, mood disorder, aripiprazole
Introduction
Effective treatment of patients with major depressive disorder (MDD) remains an 
outstanding need in psychiatry. In the past, adjunctive antipsychotics were used primar-
ily for treating psychotic symptoms in patients with MDD. However, current evidence 
indicates that these agents have antidepressant effects in patients with non-psychotic 
major depression. Recently, the atypical antipsychotic aripiprazole received approval 
from the Food and Drug Administration (FDA) as adjunctive therapy for patients with 
MDD. Given these developments, this review of the need for augmentation strategies, 
the range of options available, and the clinical evidence base for aripiprazole as the 
newest adjunctive medication for MDD was undertaken.
Epidemiology and disease burden
Major depressive disorder is a common and disabling psychiatric condition (Murray 
and Lopez 1996). Current estimates for lifetime prevalence of MDD range from 
17% to 18%, making it one of the most prevalent mental health disorders (Kessler 
et al 2003). According to the Global Burden of Disease Study (Murray and Lopez 
1996, 1997), depression currently ranks as the fourth leading cause of global disease 
burden, with the disorder affecting 13–14 million adults in the United States in a 
given year (Kessler et al 2003). By 2020, depression is projected to be the second 
leading cause of disease burden worldwide after heart disease. Furthermore, MDD 
is associated with high morbidity and mortality; for example, up to 15% of individu-
als with more severe forms of this disorder die by suicide (APA 2000). MDD also 
incurs huge health care costs: in 2000, depression (major depressive disorder, bipolar 
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depression or dysthymia) incurred an estimated cost of US 
$83.1 billion, which was related to treatment costs, loss of 
productivity and suicide-related costs (Greenberg et al 2003). 
Another study that excluded bipolar depression found that 
employees with MDD have costs of lost work time total-
ing US$31 billion compared with peers without depression 
(Stewart et al 2003).
Depression comorbid with other chronic diseases, such 
as diabetes and arthritis, worsens overall health and well-
being. Several studies have shown that there is an increased 
risk of major depression in individuals with one or more 
chronic diseases (Katon and Schulberg 1992; Noel et al 
2004; Harpole et al 2005; Katon et al 2007). Indeed, data 
suggest that there is an interactive/synergistic effect between 
depression and chronic medical conditions, resulting in a 
negative effect on health beyond a simple additive effect of 
each condition (Moussavi et al 2007). In addition, depression 
aggravates the course of various medical conditions, even 
increasing mortality in patients with heart disease and stroke 
(Frasure-Smith et al 1993; Morris et al 1993).
If left untreated, depression may develop a chronic 
course or be recurrent, and over time be associated with 
increasing disability (Andrews 2001, Solomon et al 2000). 
Given the prevalence, chronicity and associated disability 
of MDD, there has been an increased focus on the develop-
ment of new and more effective treatment options for this 
condition.
Diagnosis and neurobiology
MDD is a complex disease state with variable symptoms, 
presentation, features, and course. This variability is a 
challenge to the clinician and complicates diagnosis. The 
DSM-IV-TR defi nes MDD as the presence of single or 
multiple major depressive episodes once schizophrenia, 
schizoaffective disorder, delusional disorders, bipolar illness 
and episodes due to substance abuse or medical illness have 
been excluded (APA 2000).
Major depression is a heterogeneous disorder and, to 
date, causal mechanisms remain unclear. Psychological, 
biological, and environmental factors have all been shown 
to contribute to the development of MDD. For example, a 
recent review of twin studies estimated that about 37% of 
the risk of MDD is inherited (Sullivan et al 2000).
The early observation that many compounds that inhibit 
monoamine reuptake have antidepressant properties sug-
gested that these neurotransmitters may be involved in 
the etiology of depression. Subsequently, many abnor-
malities in the serotonin, norepinephrine, and dopamine 
systems have been identifi ed but it remains unclear which 
are primary, which are compensatory, and which are 
changes unrelated to depression (Belmaker and Agam 
2008). A possible role for serotonin, norepinephrine, and 
dopamine in various behaviors associated with depression 
has been suggested by animal studies; yet, to date, these 
relationships have not been validated in depressed human 
patients. In fact, a comparison of the symptom effects of 
two antidepressants selective for different neurotransmit-
ters – serotonin and norepinephrine – found no differences 
in the symptoms that improved, suggesting that they both 
may act through a fi nal common pathway (Nelson et al 
2005).
Alternatively, the role of neurotransmitters in the 
mediation of antidepressant action is relatively better 
established. Studies that use tryptophan depletion to lower 
serotonin and alpha-methyl-paratyrosine to inferfere with 
the synthesis of catecholamines indicate that serotonin, 
norepinephrine, and dopamine are involved in the mecha-
nism of action of most antidepressant compounds (Delgado 
et al 1990; Miller et al 1996).
Treatment and management
Treatment goals
Once a patient is diagnosed with MDD, treatment of 
MDD should aim to achieve full resolution of symptoms 
and full restoration of psychosocial and occupational 
functioning. Treatment initially focuses on the rapid 
resolution of symptoms during the acute phase with the 
goal of remission. As the patient moves into continuation 
therapy, the goal is to maintain remission and prevent 
relapse. Remission represents a pivotal stepping stone on 
the road to recovery and is the key goal of pharmacologi-
cal treatment (Figure 1).
Early achievement of symptomatic remission is critical 
to the long-term success of treatment (Kupfer 2005). 
Residual symptoms and partial response are associated 
with an increased risk of relapse, faster time to relapse, a 
more severe and chronic course, and increased functional 
impairment (social, occupational, home life) (Paykel et al 
1995; Papakostas et al 2004). The importance of achieving 
remission has been well illustrated in the Sequenced Treat-
ment Alternatives to Relieve Depression (STAR*D) study. 
As shown in Figure 2, at each treatment level, patients who 
achieved remission were less likely to relapse than those 
not achieving remission (Rush et al 2006; Rush 2007). Col-
lectively, these data validate the importance of remission as 
a clinically meaningful endpoint.
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Treatments
Antidepressants are currently the mainstay of treatment for 
depression and depressive episodes. Many different classes 
of antidepressants exist, including monoamine oxidase 
inhibitors (MOAIs), tricyclic antidepressants (TCAs), 
serotonin modulators, selective serotonin reuptake inhibi-
tors (SSRIs), dopamine-norepinephrine reuptake inhibitors 
(DNRIs), serotonin-norepinephrine reuptake inhibitors 
(SNRIs), and norepinephrine-serotonin modulators. The 
effectiveness of antidepressant medications is generally 
comparable. Although a possible advantage for dual-action 
agents has been suggested, a meta-analysis of 93 studies 
comparing dual-action agents with SSRIs found the advan-
tage, although signifi cant, was small, with a pooled response 
rate of 63.6% for dual-action agents vs 59.3% for SSRIs 
(Papakostas et al 2007b).
Despite the availability of more than two dozen different 
antidepressants, these treatments often yield inadequate 
results. Up to 70% of patients with MDD do not reach 
remission with an adequate course of one antidepressant and 
experience poorer long-term outcomes (Fava 2003; Rush et al 
2006; Trivedi et al 2006). In addition, STAR*D demonstrated 
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Figure 1 Remission is the key stepping stone between response to an acute episode and achieving full recovery (After Kupfer 1991).
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Figure 2 Remission at entry into follow-up was associated with lower relapse rates than response without remission in STAR*D study (12-month follow-up period) 
(After Rush et al 2006).
Relapse = QIDS-SR score 11.
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that, with each failed treatment trial, remission rates declined. 
Remission rates after two or three failed treatments averaged 
less than 15% (Rush et al 2006).
According to American Psychiatric Association (APA) 
practice guidelines, if a patient with MDD has not responded 
to treatment or achieved only a partial response to treatment 
after 4–8 weeks of therapy during the acute phase, a change 
in dose, a switch to a new drug, or augmentation therapy is 
recommended (American Psychiatric Association 2000). 
A range of augmentation and combination strategies have 
been used (Fava et al 2003; Rush et al 2004). The challenge 
for clinicians is to tailor and adjust treatment options for 
individual patients in order to identify the most appropriate 
treatment approach.
Augmentation and combination
strategies
Both augmentation and combination strategies have been used 
in patients with major depression. Combination strategies are 
those that use two antidepressants, each of which is approved 
as monotherapy. Augmentation strategies add an agent that is 
not conventionally used as fi rst-line monotherapy (ie, atypical 
antipsychotic, lithium, T3) to an antidepressant. Augmentation 
and combination strategies have been proposed on the assump-
tion that such combinations may have additive or synergistic 
effects (Rush et al 2006; Rutherford et al 2007). Furthermore, 
addition of a second agent in a partial responder has the prac-
tical advantage of maintaining any improvement made and 
may result in a rapid response. Notably, the effi cacy of aug-
mentation and combination treatments is not limited to partial 
responders, but has been less well studied in non-responders. 
For the purpose of this review article, we recognize the terms 
“augmentation” and “adjunctive” as similar in meaning and 
may use them interchangeably throughout the text.
Although combination approaches are commonly used, 
the evidence base is quite limited. The popular combina-
tion of bupropion and SSRI has not been examined in 
placebo-controlled studies. “Best evidence” is limited to 
an open-label, randomized comparison study in STAR*D 
(Trivedi et al 2006). Similarly, the best evidence for the 
combination of venlafaxine and mirtazapine is an open-
label, randomized comparison (McGrath et al 2006). The 
combination of mirtazapine and an SSRI has been studied 
and found effective in two controlled studies of 26 and 62 
patients, respectively (Carpenter et al 2002; Blier et al 2003). 
Desipramine added to fl uoxetine has been demonstrated to 
be effective in a small study of 39 inpatients (Nelson et al 
2004), but only half of the sample were previously treatment 
resistant. Overall, controlled trials of combination strategies 
are limited in number, are limited in sample size (largest 
is n = 62), and are variable in their requirements for prior 
treatment resistance.
A variety of agents have been used to augment antide-
pressants. The most frequently studied strategies are lithium, 
thyroid, stimulants, buspirone, pindolol, and omega-3 fatty 
acids. Addition of stimulants is one of the oldest strategies 
and most studies were small, open-label, and added dextro-
amphetamine or methylphenidate to a tricyclic or an MAOI. 
A recent placebo-controlled, double-blind trial in 60 patients 
augmented an SSRI with methylphenidate but failed to fi nd a 
signifi cant advantage for the augmentation approach (Patkar 
et al 2006a). Open-label studies of buspirone and pindolol 
suggested effi cacy but a controlled trial of buspirone failed 
(Landen et al 1998), as did two controlled trials of pindolol 
in treatment-resistant patients (Moreno et al 1997; Perez 
et al 1999).
Lithium augmentation was the fi rst approach suggested 
on the basis of a neurochemical rationale (De Montigny 
et al 1981). Subsequently, lithium augmentation has been 
studied in 10 placebo-controlled trials and a meta-analysis 
of these trials has been reported (Crossley and Bauer 2007). 
Although the meta-analysis showed evidence of effi cacy, the 
value of lithium augmentation continues to be debated. The 
largest controlled lithium study included 61 patients but all 
the others were small studies (35 patients). Few included 
clearly resistant patients, and the only study that did include 
treatment-resistant patients failed to fi nd any advantage for 
lithium (Nierenberg et al 2003). Addition of triiodothyronine 
(T3) has also received considerable attention. A recent meta-
analysis of  T3 studies found evidence for effi cacy; however, 
when limited to placebo-controlled trials, only 75 patients 
were studied in four trials and the difference between T3 
and placebo was not signifi cant (Aronson et al 1996). All of 
these controlled trials added T3 to a tricyclic antidepressant. 
In the open, randomized STAR*D comparison (Nierenberg 
et al 2006), thyroid was signifi cantly better tolerated than 
lithium augmentation and appeared to be effective. The other 
augmentation strategy with a growing literature is the addi-
tion of omega-3 fatty acids. Although results were variable, 
a meta-analysis and review document only ten double-blind, 
placebo-controlled studies in 329 patients with mood dis-
orders who were receiving omega-3 PUFAs for 4 weeks 
(Lin and Su 2007). The results demonstrated a signifi cant 
effect for omega-3-fatty acid but signifi cant heterogeneity 
was noted, as was an indication of publication bias. Study 
designs, patient samples, dosing, and omega-3 constituents 
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were variable. Finally, as with several other strategies, the 
effi cacy of omega-3 in antidepressant-resistant patients needs 
further study.
Although other augmentation strategies have been 
suggested, the data for these are more limited. One large 
trial (n = 308) of modafi nil in SSRI partial responders with 
prominent fatigue and sleepiness did show the drug to be 
more effective than placebo (Fava et al 2005). One controlled 
trial of folate in 127 depressed patients showed signifi cant 
effi cacy in women but not in men (Coppen and Bailey 2000). 
Augmentation studies of testosterone have been negative. 
Augmentation with estrogen or estrogen/progesterone 
combinations in post- or peri-menopausal women have been 
inconsistent (Morgan et al 2005, Dias et al 2006).
Atypical augmentation
Prior to 1980, more than 30 studies explored the use of 
typical antipsychotics in MDD (Nelson 1987). These 
trials are limited particularly by the use of earlier diagnostic 
systems; nevertheless, the fi ndings suggested that patients 
experienced some relief with these agents. They were 
never recognized as true antidepressants, perhaps because 
they were not effective for treatment of two core symp-
toms of depression – loss of interest and motor retardation 
(Raskin et al 1970). Two formulations of an antipsychotic 
(perphenazine) and an antidepressant (amitriptyline) were 
licensed for use in depression. However, the use of the 
typical antipsychotics in non-psychotic depression declined 
rapidly during the 1980s with recognition of their risk of 
tardive dyskinesia.
The advent of second-generation antipsychotics with an 
improved safety profi le has prompted their exploration as 
effective agents for the treatment of MDD. In 1999, Ostroff 
and Nelson reported the apparent value of adding risperi-
done in 8 outpatients who had not responded to an SSRI 
(Ostroff and Nelson 1999). In 2001, Shelton et al reported 
the fi rst controlled study of olanzapine and fl uoxetine vs 
either drug with placebo in 28 patients showing an advantage 
for the combination (Shelton et al 2001). Subsequently, a 
number of open and controlled studies followed. In 2007, 
Papakostas et al published a review and meta-analysis of 
atypical augmentation studies (Papakostas et al 2007a). They 
found 10 studies (olanzapine 5, quetiapine 3, risperidone 2). 
The studies included 4 smaller samples of 15–58 patients 
and 6 larger samples of 100–303 patients. All included 
patients with non-psychotic major depression. Different 
from the previous literature, several of these studies required 
evidence of prior treatment failure, usually to one historical 
and one prospective treatment trial. The meta-analysis found 
that the trials as a group demonstrated effi cacy, although 
several individual studies did not (Figure 3). The risk ratio 
for remission comparing atypical antipsychotics with placebo 
was 1.75 (95% CI 1.36, 2.24; p  0.0001) and for response 
was 1.35 (95% CI 1.13, 1.63; p = 0.001). Pooled remission 
rates were 47.2% and 22.3% for the atypical agents and 
placebo, respectively. Pooled response rates were 57.2% and 
35.4%, respectively. Although this meta-analysis showed no 
difference in overall discontinuation rates between atypical 
antipsychotics and placebo, the rate of discontinuations 
due to adverse events was more than three-fold higher in 
patients treated with atypical antipsychotic agents than 
placebo (p  0.0001).
Aripiprazole represents one of the most recently devel-
oped second-generation atypical antipsychotics. Effi cacy for 
aripiprazole augmentation in depression was demonstrated 
in two large, randomized, double-blind 14-week studies 
(Berman et al 2007b; Marcus et al 2008). A third study is 
currently ongoing. Based on the fi ndings to date, aripiprazole 
recently received approval from the FDA for the treatment of 
major depression as an adjunctive agent to standard antide-
pressant therapy (ADT). Initial open-label studies reported 
the effi cacy of adjunctive aripiprazole in patients with depres-
sion (Barbee et al 2004; Papakostas et al 2005; Simon and 
Nemeroff 2005; Worthington et al 2005; Patkar et al 2006b; 
Hellerstein et al 2007; Pae et al 2007; Rutherford et al 2007; 
Schule et al 2007). An overview of the pivotal clinical trial 
program for aripiprazole in MDD is provided in Table 1. 
This program provides the most rigorous dataset available 
for any single agent evaluated for augmentation treatment of 
MDD, supported by large patient populations, randomized 
and placebo-controlled study designs, and implementation 
of historical and prospective demonstration of antidepressant 
unresponsiveness (Table 1). The remainder of this review 
focuses on the fi ndings of these studies.
Focus on aripiprazole
Pharmacological rationale
Although the mechanism of action of augmentation is not 
well understood, it is possible that the distinct pharma-
cological profi le of aripiprazole may make it a suitable 
adjunctive agent for the treatment of MDD. Differing from 
conventional antipsychotics, which were thought to have 
essentially a one-dimensional effect related to D
2
 antago-
nism, the atypical drugs have neuropharmacologic profi les 
that are quite different and may have different implications 
in depression. Thus, although these agents appear to have 
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similar effi cacy in schizophrenia, it is not clear that they 
have similar effi cacy in depression. For example, all of the 
atypical agents have 5-HT
2
 antagonist effects that might 
contribute to antidepressant effects. The synergistic effects 
of olanzapine and fl uoxetine on synaptic levels of 5HT, NE, 
and dopamine may be useful, and for ziprasidone the possible 
addition of 5-HT and norepinephrine reuptake blockade is of 
potential interest. For aripiprazole, the interesting features are 
its partial-agonist activity at the D
2
/D
3
 receptors, in addition to 
partial-agonist activity at the serotonin 1A (5-HT
1A
) receptor 
(Shapiro et al 2003; Jordan et al 2004, Stark et al 2007). An 
agent, such as aripiprazole, that engages several mechanisms 
of action might be particularly effective in depression; 
however, all of these possible synergies are hypothetical and 
it is unclear how they translate into clinical effi cacy.
Pharmacokinetics and dosing
Pharmacokinetic interaction studies have shown that 
aripiprazole 2–20 mg/kg does not affect the clearance of 
escitalopram, fl uoxetine, paroxetine, sertraline, or venla-
faxine; thus, no dosage adjustment is required for these 
antidepressants when aripiprazole is added. Across four 
studies, aripiprazole had no clinically meaningful effects 
on the pharmacokinetics of these standard antidepres-
sant therapies (escitalopram, 10–20 mg/day; fl uoxetine, 
20–40 mg/day; paroxetine controlled-release, 37.5–50 mg/day; 
sertraline, 100–150 mg/day; or venlafaxine extended-release, 
150–225 mg/day) in either healthy subjects or patients with 
MDD (personal communication/manuscript submitted). 
However, fl uoxetine and paroxetine are both inhibitors of 
CYP2D6, and are likely to increase aripiprazole plasma levels 
(Abilify 2007). The pivotal augmentation studies used the 
same fl exible-dose design. Patients randomized to receive 
adjunctive aripiprazole were treated with a starting dose of 
5 mg/day, which could be increased weekly in 5 mg/day 
increments to a maximum dose of 15 mg/day (patients receiv-
ing fl uoxetine or paroxetine CR, due to their CYP2D6 inhibi-
tion increasing aripiprazole levels) or 20 mg/day (all other 
patients) based on assessment of tolerability and clinical 
response. If tolerated, all patients were to receive a target 
minimum dose of 10 mg/day. Doses could be decreased at 
any visit, based on tolerability; patients unable to tolerate 
5 mg/day could have their dose decreased to 2 mg/day. The 
FDA have approved an initial dose of adjunctive aripiprazole 
Shelton et al
Shelton et al
Corya et al
Keitner et al
Khullar et al
Mattingly et al
Mclntyre et al
Thase et al
Thase et al
Gharabawi et al
Combined
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Figure 3 Meta-analysis of studies of atypical antipsychotic augmentation of antidepressants. Papakostas GI, Shelton RC, Smith J, et al 2007a.  Augmentation of antidepressants 
with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis.  J Clin Psychiatry, 68:826–31. Copyright © 2007 Physicians Postgradu-
ate Press. Reprinted with permission.
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in patients with MDD of 2–5 mg/day, with a recommended 
target dose of 5–10 mg/day and a maximal dose of 15 mg/day. 
However, the relative effi cacy of different doses has not been 
tested in MDD in fi xed-dose studies. Some case studies have 
been published showing effi cacy of aripiprazole augmentation 
at a dose as low as 3 mg/day (Terao 2007).
Effi cacy
In patients with major depression without psychosis who 
showed an inadequate response to ADT, adjunctive aripip-
razole has been shown to augment antidepressant effi cacy 
in two 14-week, double-blind, randomized trials of identi-
cal design (Berman et al 2007b; Marcus et al 2008). The 
studies comprised a screening phase, an 8-week prospective 
treatment phase, and a 6-week randomization phase. During 
prospective treatment, patients received escitalopram, fl uox-
etine, paroxetine controlled-release, sertraline or venlafaxine 
extended-release, each with single-blind adjunctive placebo. 
Subjects with an inadequate response (50% reduction 
HAM-D17 Total, HAM-D 17  14 and Clinical Global 
Impressions-Improvement [CGI-I]  3 at the end of the 
ADT phase) continued ADT and were randomly assigned 
to adjunctive placebo or adjunctive aripiprazole; subjects 
were blinded to randomization (ie, the use of single-blind 
placebo). In the Marcus et al study, a total of 381 patients 
were randomized to adjunctive placebo (n = 190) or adjunc-
tive aripiprazole (n = 191) in the randomized, double-blind 
treatment phase (Marcus et al 2008). In the Berman et al 
study, a total of 178 patients were randomly assigned to 
adjunctive placebo and 184 to adjunctive aripiprazole 
(Berman et al 2007b). It is also notable that, in both studies, 
the use of benzodiazepines or other sleep aids were not 
permitted, so that sedation/somnolence-inducing agents 
would not confound the effi cacy results.
In both studies, remission rates (defi ned as a MADRS 
Total score of 10 and 50% reduction in MADRS Total 
score from baseline [end of prospective treatment]) were 
signifi cantly higher with adjunctive aripiprazole than with 
adjunctive placebo: 26.0% versus 15.7%, p = 0.01 (Berman 
et al 2007b); and 25.4% versus 15.2%, p  0.05 (Marcus 
et al 2008). Remission was achieved in signifi cantly more 
patients with adjunctive aripiprazole versus placebo early in 
both studies, as early as week 1 (Berman et al 2007b) and 
week 2 (Marcus et al 2008).
Although remission is critical as an endpoint in real-life 
practice, for registration purposes the primary endpoint 
of these studies was the mean change in MADRS Total 
score from baseline to Week 6. Both studies showed sig-
nifi cant improvements with adjunctive aripiprazole over 
placebo on this measure: −8.8 vs −5.8, p  0.001 (Berman 
et al 2007b); −8.5 vs −5.7, p = 0.001 (Marcus et al 2008) 
(Figure 4). Again, the onset of a signifi cant difference with 
adjunctive aripiprazole over placebo was apparent by week 
1 in the study by Marcus et al (2008) and week 2 in the study 
Table 1 Overview of clinical data for aripiprazole in major depressive disorder
Study Aripiprazole starting 
dose (permitted 
adjustment), mg
Comparator Duration Total n Primary endpoint Primary publication
CN138–139 5 (2–20) Placebo 6 weeks 362 Mean change in MADRS from baseline 
to Week 6: –8.8 vs –5.8, p < 0.001
Berman et al 2007
CN138–163 5 (2–20) Placebo 6 weeks 381 Mean change in MADRS from baseline 
to Week 6: –8.5 vs –5.7, p = 0.001
Marcus et al 2008
CN138–462 10 (10–20) N/A 15 days 38 No meaningful effects on the 
pharmacokinetic parameters for 
venlafaxine (Cmax, Cmin, Tmax, AUC(TAU)) 
when administered alone and 
co-administered with aripiprazole
Boulton et al in press
CN138–463 10 (no adjustment) N/A 15 days 25 No meaningful effects on the 
pharmacokinetic parameters for 
escitalopram (Cmax, Cmin, Tmax, AUC(TAU)) 
when administered alone and 
co-administered with aripiprazole
Boulton et al in press
CN138–164 Continuation dose from 
Studies CN138–139 and 
CN138–163
Placebo 52 weeks 930 Incidence of treatment-emergent 
adverse events
Berman et al 2008
CN138–165 5 (2–20) Placebo 6 weeks 349 Incidence of treatment-emergent 
adverse events
Unpublished data
Neuropsychiatric Disease and Treatment 2008:4(5)944
Nelson et al
by Berman et al (2007b), with the adjunctive aripiprazole 
group continuing to show improvement throughout the 
study. Response, defi ned as 50% improvement in MADRS 
total score from baseline, was achieved by signifi cantly 
more patients in the adjunctive aripiprazole than adjunc-
tive placebo group in both studies at endpoint. Additional 
measures of effi cacy – the Clinical Global Impression of 
Severity (CGI-S) scores and Clinical Global Impression of 
Improvement (CGI-I) response rates – showed signifi cantly 
greater improvements with adjunctive aripiprazole compared 
with adjunctive placebo (p  0.05).
Effi cacy in diffi cult-to-treat subgroups
In a post-hoc analysis, data from the two double-blind effi -
cacy trials (effi cacy sample, n = 722) were pooled in order 
to determine the effi cacy of aripiprazole in subpopulations 
of patients with MDD. Although it has been suggested that 
antidepressants may be less effective in anxious depression 
(Fava et al 2008) and that tricyclics may be less effective 
in atypical depression, adjunctive aripiprazole showed 
signifi cantly greater effi cacy than placebo in patients with 
anxious depression (defi ned by a total score of 7 on the 
anxious/somatization factor of the HAM-D17) or atypical 
depression (defi ned using the Inventory for Depressive 
Symptomatology-Self Rated (IDS-SR) to determine the 
presence of DSM criteria for Major Depression with Atypi-
cal Features) (Thase et al 2007). In addition, adjunctive 
aripiprazole was effective in both partial responders (25% 
but 50% improvement on the MADRS Total score) and 
minimal responders (25% improvement on the MADRS 
Total score). Change scores on the MADRS Total score 
were −7.2 with aripiprazole and −5.4 with placebo in partial 
responders and −9.4 with aripiprazole and −6.0 with placebo 
in minimal responders (Thase et al 2007).
Tolerability
Overall in the clinical studies, adjunctive aripiprazole was 
well tolerated. There was a high completion rate in both 
studies (adjunctive aripiprazole, 87.9%; adjunctive placebo, 
90.9% [Berman et al 2007b]; adjunctive aripiprazole, 84.8%; 
adjunctive placebo, 85.3% [Marcus et al 2008]), and a low 
discontinuation rate due to adverse events (AEs) (adjunctive 
aripiprazole, 3.3%; adjunctive placebo, 2.3% [Berman et al 
2007b]; adjunctive aripiprazole, 3.7%; adjunctive placebo, 
1.1% [Marcus et al 2008]).
Akathisia was the most common AE reported with adjunc-
tive aripiprazole in the two samples occurring in 24.8% of the 
patients. However, a post-hoc pooled analysis of the 737 patients 
in the two studies showed that akathisia was of mild to moderate 
severity in 92% of the cases, only 3 of  371 aripiprazole-treated 
patients (0.8%) discontinued treatment because of it, and half 
of the akathisia events resolved at endpoint. The most common 
interventions associated with resolution were dose reduction 
(51%) and no intervention (36%) (Nelson et al 2007).
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Figure 4 Change from baseline in MADRS Total score (last observation carried forward) in the two randomized, double-blind, placebo-controlled studies of adjunctive 
aripiprazole.
**p  0.01 vs placebo. 
***p  0.001 vs placebo; MADRS Total score is rated from 0 to 60, where a negative change indicates improvement.
Abbreviations: MADRS, Montgomery – Asberg Depression Rating Scale; LOCF, last observation carried forward.
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Because both of these studies used a “guided-flexible” 
dosing strategy that limited changes in aripiprazole 
dose to 5 mg in weekly increments and recommended a 
minimum dose of 10 mg/day, the rates of akathisia may 
overestimate rates obtained in clinical practice in which 
dosing is further individualized. Aiming for the minimum 
effective dose may be a prudent strategy. Indeed, in the 
Berman et al study, approximately half of the patients 
who completed the study and responded to adjunctive 
aripiprazole were receiving a dose of 10 mg/day or less 
(Berman et al 2007b).
Mean weight gain with adjunctive aripiprazole was 
higher than adjunctive placebo in both studies (+2.01 ± 
0.17 kg vs +0.34 ± 0.18 kg, p  0.001 [Berman et al 
2007b]; +1.47 ± 0.16 kg vs +0.42 ± 0.17 kg, p  0.001 
[Marcus et al 2008]) over a 6-week treatment period. Impor-
tantly, no patients in either study discontinued treatment 
due to weight gain. Signifi cantly, a pooled analysis of the 
metabolic parameters across both studies showed that the 
effects of adjunctive aripiprazole on mean change in body 
weight did not appear to be specifi c to any baseline body 
mass index category or to any dose of aripiprazole (Berman 
et al 2007a). Furthermore, the increase in body weight 
occurred in the absence of a clinically signifi cant increase 
in other metabolic measures (Berman et al 2007a). During 
the double-blind, randomized treatment phase in Berman 
et al, two patients experienced suicidal ideation, both in 
subjects who were receiving placebo (Berman et al 2007a). 
In the second study, no suicide-related AEs were reported 
with either adjunctive aripiprazole or placebo during the 
double-blind randomized phase.
No new cases of tardive dyskinesia were observed during 
the study; however, the 6-week duration of the trials may 
underestimate rates observed with long-term treatment. 
Correll et al reviewed rates of tardive dyskinesia observed 
with the second-generation antipsychotics, and concluded 
that these rates (0.8% in non-elderly adults) were substan-
tially lower than those observed with conventional agents 
(5.4% in adults on haloperidol) (Correll et al 2004). Never-
theless, tardive dyskinesia can occur with all antipsychotic 
agents. The rate of tardive dyskinesia in populations with 
MDD treated with aripiprazole in the 1-year safety study 
(0.4%) (Berman et al 2008) was comparable to what has 
been reported for other atypicals in other populations in 
long-term studies (0.8%; Correll 2004) and lower than that 
seen with olanzapine–fl uoxetine combination (1.8%) (Corya 
et al 2003). All of the cases resolved within 45 days of dis-
continuing medication.
Functioning
In addition to effi cacy for symptoms of major depression, 
an ideal treatment will also reduce or minimize functional 
disability associated with the disorder. The Sheehan Dis-
ability Scale (SDS) is an instrument used to assess the 
impact of illness-related impairment in three domains of 
functioning – work/school, social life, and family life/home 
responsibilities. Patients with MDD display greater func-
tional impairment in social and family areas rather than work 
(Kessler et al 2003). Both the double-blind studies used the 
SDS and found that adjunctive treatment of standard ADT 
with aripiprazole improved family and social functioning 
(both p  0.05). In addition, adjunctive aripiprazole treat-
ment did not adversely affect sexual functioning in either 
study, as measured on the Sexual Function Index (SFI) scale, 
and resulted in signifi cant improvements in ‘interest in sex’ 
(p  0.001) and ‘sexual satisfaction’ (p = 0.015) items during 
one of the studies (Marcus et al 2008).
Conclusions
Achieving remission early in the course of depression is criti-
cal for the success of long-term treatment outcomes. A range 
of augmentation and combination strategies have been used in 
order to increase the chance of achieving remission. Indeed, 
for some patients, initiating combination and augmentation 
strategies earlier in treatment may increase the likelihood of 
remission; however, this strategy has not been well studied.
Although augmentation and combination strategies 
are commonly used for treatment of MDD, until recently 
there were relatively few large, double-blind, randomized, 
placebo-controlled trials to support this approach. As reviewed 
above, even the controlled trials used sample sizes that were 
usually very small. In addition, until recently treatment 
resistance was often poorly defi ned, if at all. The studies of 
the atypical antipsychotics are the fi rst class of augmentation 
strategies to attempt to defi ne unresponsive depression using 
adequate historical and prospective antidepressant trials. 
There is now growing evidence for the effi cacy of atypical 
antipsychotics for adjunctive treatment of depressive symp-
toms of MDD in the absence of psychotic symptoms. In two 
large clinical trials, the addition of aripiprazole to standard 
ADT monotherapy was signifi cantly more effective than the 
addition of placebo for the treatment of depression in patients 
with MDD who failed to respond to one prospective ADT trial 
and one to three historical trials during the current episode. 
Whether aripiprazole is more effective than other atypical 
agents has not been studied. Nor has the effi cacy of aripiprazole 
been compared with lithium, thyroid or other augmentation 
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strategies. These questions, as well as the long-term use of 
these agents in depression, await further study.
Key clinical questions
How do you decide when to augment versus switch 
in MDD?
• Clinical wisdom, as refl ected in surveys and treatment 
choice in STAR*D, suggests that augmentation is favored 
in partial responders. This is primarily based on practical 
considerations – namely, that addition of a second agent 
allows the initial response to be maintained while a switch 
might not.
• However, in patients with minimal response, data com-
paring augmentation strategies with switch options are 
lacking.
• The tolerability of the initial agent plays a role here. 
A poorly tolerated initial agent suggests a switch.
Is there an accepted defi nition of inadequate treatment 
response/partial response or treatment-resistant patients?
• No defi nition of treatment-resistant depression has been 
adequately validated.
• Lack of response to a minimum of two adequate trials 
of medication from different classes has been proposed 
as the basic defi nition of treatment resistance in MDD 
(Thase 2002).
• The STAR*D findings suggest that remission rates 
drop considerably after two failed trials, supporting the 
recommendation that two failed trials defi nes treatment 
resistance.
How does onset of action infl uence your decision when 
choosing a pharmacologic agent for MDD?
• Antidepressant medications are generally considered to 
have a delayed onset of action.
• In STAR*D, one half of the patients achieved remission 
during weeks 6–12.
• However, evidence of initial response can be observed 
in 1 or 2 weeks.
• Compared with switching, augmentation strategies may 
be more rapid, especially since no time is lost tapering 
the initial treatment.
• Early response to antidepressants is an unmet medical 
need and one that should be addressed in future treatment 
paradigms.
How can we manage side effects of adjunctive aripiprazole 
therapy?
• The key to successful treatment with any agent is aware-
ness of the clinical profi le and education of the patient 
about the drugs used.
• As clinical experience with aripiprazole has grown, some 
management strategies for the treatment of side effects 
have emerged.
• Although few predictors of akathisia have been identifi ed, 
in patients with a history of akathisia, a more gradual 
dosing strategy might be used. Rates of akathisia appear 
higher in patients under age 40 years.
• For mild–moderate akathisia, dose reduction is an option 
if it does not compromise effi cacy. If tolerable, akathisia 
appears to abate with time.
• Concomitant medications (eg, benzodiazepines, beta-
blockers, or anticholinergic agents) may be useful for 
more severe akathisia but their effi cacy in this situation is 
based more on clinical experience than controlled trials. 
Given high rates of improvement with time, it is not clear 
that these interventions are better than time.
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